文献速递临床生化分子诊断临床免疫

循环微生物代谢物与前列腺癌肠-前列腺轴:实验室生物标志物与治疗反应的意义

Circulating microbial metabolites and the gut-prostate axis in prostate cancer: Implications for laboratory biomarkers and therapeutic response.
PubMed 文献 · Clin Chim Acta · 2026-05-14

本综述综合微生物组来源代谢物作为前列腺癌可测量生物标志物的现有证据。肠道微生物代谢产生短链脂肪酸、次级胆汁酸、吲哚衍生物、多胺和内毒素相关信号等循环分子,可调节炎症、上皮屏障完整性和全身免疫反应。这些代谢物可通过液相色谱-质谱联用和气相色谱-质谱联用检测,有潜力整合入实验室生物标志物 panel,并可能提升 PSA 等现有标志物的诊断和预后性能。

要点

  • 肠道微生物代谢物可在血清或血浆中检测,支持其作为前列腺癌实验室生物标志物的潜力。
  • 微生物代谢物可调节炎症、屏障完整性和免疫反应,并参与激素转化与肠肝循环。
  • 多组学方法有助于阐明微生物活动与治疗反应之间的机制联系。

核心结论

  • 表征循环微生物组来源代谢物可能提升现有生物标志物(如前列腺特异性抗原)的诊断和预后性能。
  • 建立跨 diverse 患者群体的可重复微生物代谢特征是将微生物组信息生物标志物转化为下一代诊断和预后工具的关键。

研究设计与样本

  • 本综述综合了微生物组来源代谢物作为前列腺癌可测量生物标志物的现有证据。

主要发现

  • 微生物代谢膳食底物产生循环分子,包括短链脂肪酸、次级胆汁酸、吲哚衍生物、多胺和内毒素相关信号。
  • 这些分子可调节炎症、上皮屏障完整性和参与肿瘤进展的全身免疫反应。
  • 肠道微生物参与类固醇转化和激素的肠肝循环,可能影响循环雄激素和雌激素水平。
  • 许多微生物代谢物可使用液相色谱-质谱联用和气相色谱-质谱联用等验证分析平台在血清或血浆中检测。
  • 新兴多组学方法结合宏基因组学、代谢组学、宿主转录组学和免疫分析,开始阐明微生物活动与治疗反应之间的机制联系。

临床怎么用

  • 从临床化学角度,表征循环微生物组来源代谢物可能增强现有生物标志物的诊断和预后性能。
  • 循环微生物组来源代谢物可能为疾病进展和治疗反应的无创监测提供新机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer progression and treatment response are influenced not only by tumor genomics and androgen receptor signaling but also by systemic host-microbiome interactions along the gut-prostate axis. Increasing evidence indicates that gut microbial metabolism produces bioactive compounds that circulate in human body fluids and can influence immune regulation, hormone metabolism, and therapeutic outcomes. This review synthesizes current evidence on microbiome-derived metabolites that may serve as measurable biomarkers relevant to prostate cancer biology and clinical laboratory diagnostics. Microbial metabolism of dietary substrates generates circulating molecules-including short-chain fatty acids, secondary bile acids, indole derivatives, polyamines, and endotoxin-associated signals-that can modulate inflammation, epithelial barrier integrity, and systemic immune responses involved in tumor progression. In addition, intestinal microbes participate in steroid transformation and enterohepatic cycling of hormones, potentially influencing circulating androgen and estrogen levels that contribute to androgen-driven prostate cancer development and adaptation under androgen deprivation therapy. Importantly, many of these microbial metabolites are detectable in serum or plasma using validated analytical platforms such as liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry, supporting their potential integration into laboratory biomarker panels. Emerging multi-omics approaches combining metagenomics, metabolomics, host transcriptomics, and immune profiling are beginning to clarify mechanistic links between microbial activity and therapy response, including variability in outcomes with androgen-targeted agents, chemotherapy, radiotherapy, and immune checkpoint inhibitors. From a clinical chemistry perspective, characterization of circulating microbiome-derived metabolites may enhance the diagnostic and prognostic performance of established biomarkers such as prostate-specific antigen while providing new opportunities for non-invasive monitoring of disease progression and treatment response. Establishing reproducible microbial metabolic signatures across diverse patient populations will be essential to translate microbiome-informed biomarkers into next-generation diagnostic and prognostic tools in prostate cancer management.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Tan MW, Clister D, Chandra QM, et al. Circulating microbial metabolites and the gut-prostate axis in prostate cancer: Implications for laboratory biomarkers and therapeutic response. Clin Chim Acta. 2026. PMID: 42140378. doi:10.1016/j.cca.2026.121086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。